Known targets — ChEMBL curated mechanism
ACHECHRM1CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNG
The experimentally established mechanism targets of Iodide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL135136 | 0.98 | — | — | |
| Hydrochloric Acid SCHEMBL9541663 | 0.95 | NPC1 (0.32) | NPC1POLBRAB9ASMN1; SMN2 | |
| Iodide SCHEMBL5366846 | 0.77 | KDM4E (0.42) | NPC1POLBRAB9ASMN1; SMN2 | |
| SCHEMBL13215505 | 0.74 | — | — | |
| Benzene SCHEMBL9542509 | 0.73 | KDM4E (0.42) | NPC1POLBRAB9ASMN1; SMN2 | |
| Bromide SCHEMBL11484493 | 0.73 | NPC1 (0.41) | NPC1POLBRAB9ASMN1; SMN2 | |
| Iodide SCHEMBL9390139 | 0.72 | KDM4E (0.41) | — | |
| SCHEMBL6162141 | 0.71 | CYP2D6 (0.47) | NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL31130749 | 0.71 | CYP2D6 (0.47) | NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL950597 | 0.70 | KDM4E (0.42) | NPC1POLBRAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3394080-A1 | LIPID-LINKED PRODRUGS | The University Of British Columbia (CA) | 2018-10-31 | — | — | EP | disclosed |
| US-20170248589-A1 | METHOD OF MEASURING INTERACTION BETWEEN MOLECULES | PHARMADIAGNOSTICS NV (BE) | 2017-08-31 | — | — | US | disclosed |
| WO-2017106957-A1 | LIPID-LINKED PRODRUGS | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2017-06-29 | — | — | WO | disclosed |
| US-9678066-B2 | Method and kit for measuring interaction between molecules | PHARMADIAGNOSTICS NV (BE) | 2017-06-13 | — | — | US | disclosed |
| EP-2628007-B1 | METHOD FOR COATING NANOPARTICLES | PHARMA DIAGNOSTICS NV (BE) | 2017-03-15 | — | — | EP | disclosed |
| US-20150024402-A1 | METHOD AND KIT FOR MEASURING INTERACTION BETWEEN MOLECULES | PHARMADIAGNOSTICS NV (BE) | 2015-01-22 | — | — | US | disclosed |
| EP-2102165-A2 | N-(METHYL)-1H-PYRAZOL-3-AMINE, N-(METHYL)-PYRIDIN-2-AMINE AND N-(METHYL)-THIAZOL-2-AMINE DERIVATIVES FOR THE TREATMENT OF DISEASES ASSOCIATED WITH AMYLOID OR AMYLOID-LIKE PROTEINS, LIKE E.G. ALZHEIMER'S | AC Immune S.A. (CH) | 2009-09-23 | — | — | EP | disclosed |
| WO-2008061795-A2 | N- (METHYL) -1H- PYRAZOL- 3 -AMINE, N- (METHYL) -PYRIDIN-2-AMINE AND N- (METHYL) -THIAZ0L-2-AMINE DERIVATIVES FOR THE TREATMENT OF DISEASES ASSOCIATED WITH AMYLOID OR AMYLOID-LIKE PROTEINS, LIKE E.G. ALZHEIMER'S | AC IMMUNE SA (CH) | 2008-05-29 | — | — | WO | disclosed |
| WO-2007125398-A2 | : SULFONAMIDE COMPOUNDS AS ANTAGONISTS OF THE N-TYPE CALCIUM CHANNEL | PFIZER JAPAN INC. (JP) | 2007-11-08 | — | — | WO | disclosed |
| EP-0675133-A1 | 13-Substituted milbemycin derivatives, their preparation and use | SANKYO COMPANY LIMITED (JP) | 1995-10-04 | — | — | EP | disclosed |
| EP-0233763-A2 | 2-Substituted quinoline dioic acids | MERCK FROSST CANADA INC. (CA) | 1987-08-26 | — | — | EP | disclosed |
| EP-0194901-A2 | Isoprenoidamine derivatives, compositions containing them, their preparation, and their use | SHIONOGI & CO., LTD. (JP) | 1986-09-17 | — | — | EP | disclosed |